128
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Genetic Markers for Ovarian Cancer Risk: Are we Close to Seeing a Clinical Impact?

Pages 565-567 | Published online: 24 Aug 2012

References

  • Siegel R , NaishadhamD, JemalA. Cancer statistics, 2012. CA Cancer J. Clin.62(1) , 10–29 (2012).
  • Buys SS , PartridgeE, BlackA et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305(22) , 2295–2303 (2011).
  • Partridge E , KreimerAR, GreenleeRT et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet. Gynecol. 113(4) , 775–782 (2009).
  • Welcsh PL , KingMC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet.10(7) , 705–713 (2001).
  • Antoniou A , PharoahPD, NarodS et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72(5) , 1117–1130 (2003).
  • Antoniou AC , CunninghamAP, PetoJ et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br. J. Cancer 98(8) , 1457–1466 (2008).
  • Gayther SA , PharoahPD. The inherited genetics of ovarian and endometrial cancer. Curr. Opin. Genet. Dev.20(3) , 231–238 (2010).
  • Bolton KL , GandaC, BerchuckA, PharaohPD, GaytherSA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J. Intern. Med.271(4) , 366–378 (2012).
  • Song H , RamusSJ, TyrerJ et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat. Genet. 41(9) , 996–1001 (2009).
  • Goode EL , Chenevix-TrenchG, SongH et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat. Genet. 42(10) , 874–879 (2010).
  • Gail MH . Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J. Natl Cancer Inst.100(14) , 1037–1041 (2008).
  • Witte JS , HoffmannTJ. Polygenic modeling of genome-wide association studies: an application to prostate and breast cancer. OMICS15(6) , 393–398 (2011).
  • Machiela MJ , ChenCY, ChenC, ChanockSJ, HunterDJ, KraftP. Evaluation of polygenic risk scores for predicting breast and prostate cancer risk. Genet. Epidemiol.35(6) , 506–514 (2011).
  • Goldstein DB . Common genetic variation and human traits. N. Engl. J. Med.360(17) , 1696–1698 (2009).
  • Wentzensen N , BlackA, JacobsK et al. Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the prostate, lung, colorectal, and ovarian cancer screening trial. PLoS ONE 6(7) , e21731 (2011).
  • Ratner E , LuL, BoekeM et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 70(16) , 6509–6515 (2010).
  • Keane FK , RatnerES. The KRAS-variant genetic test as a marker of increased risk of ovarian cancer. Rev. Obstet. Gynecol.3(3) , 118–121 (2010).
  • Pharoah PD , PalmieriRT, RamusSJ et al. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin. Cancer Res. 17(11) , 3742–3750 (2011).

▪ Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.